Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MASP2 | O00187 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.39 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5221937 | 0.99 | PNMT (0.48) | PNMTCTSDBACE1BACE2SLC2A1 | |
| SCHEMBL5393980 | 0.86 | CTSD (0.44) | CTSDBACE1BACE2ADRB2ADRB1 | |
| SCHEMBL5404892 | 0.85 | CSNK1E (0.51) | CTSDBACE1BACE2ADRB2SPPL2A | |
| Hydrochloric Acid SCHEMBL5217734 | 0.85 | CTSD (0.43) | CTSDBACE1BACE2ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL4692419 | 0.84 | CSNK1E (0.50) | CTSDBACE1BACE2ADRB2SPPL2A | |
| SCHEMBL5223736 | 0.81 | BACE1 (0.57) | PNMTCTSDBACE1BACE2SLC2A1 | |
| SCHEMBL5223728 | 0.81 | BACE1 (0.57) | PNMTCTSDBACE1BACE2SLC2A1 | |
| SCHEMBL5396597 | 0.79 | SLC6A2 (0.40) | CTSDBACE1BACE2ADRB2SPPL2A | |
| Hydrochloric Acid SCHEMBL5222425 | 0.78 | SLC6A2 (0.40) | CTSDBACE1BACE2ADRB2SPPL2A | |
| Hydrochloric Acid SCHEMBL5219422 | 0.77 | BACE1 (0.36) | CTSDBACE1BACE2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | PNMT 6/4885CTSD 384/4885BACE1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.